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Management of patients with liver derangement during the 
COVID-19 pandemic: an Asia-Pacific position statement
Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Alex Thompson, Jidong Jia, Jinlin Hou, Cosmas Rinaldi Adithya Lesmana, Adityo Susilo, 
Yasuhito Tanaka, Wah-Kheong Chan, Ed Gane, Arlinking K Ong-Go, Seng-Gee Lim, Sang Hoon Ahn, Ming-Lung Yu, Teerha Piratvisuth, 
Henry Lik-Yuen Chan, on behalf of the Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic
The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients with COVID-19 with 
abnormal liver function, either in the form of hepatitis, cholestasis, or both. The clinical implications of liver 
derangement might be variable in different clinical scenarios. With growing evidence of its clinical significance, it 
would be clinically helpful to provide practice recommendations for various common clinical scenarios of liver 
derangement during the COVID-19 pandemic. The Asia-Pacific Working Group for Liver Derangement during the 
COVID-19 Pandemic was formed to systematically review the literature with special focus on the clinical management 
of patients who have been or who are at risk of developing liver derangement during this pandemic. Clinical scenarios 
covering the use of pharmacological treatment for COVID-19 in the case of liver derangement, and assessment and 
management of patients with chronic hepatitis B or hepatitis C, non-alcoholic fatty liver disease, liver cirrhosis, and 
liver transplantation during the pandemic are discussed.
Background
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) is a novel zoonotic coronavirus that can 
cause an acute respiratory illness in humans, known as 
COVID-19.1 COVID-19 is a global health problem not only 
because of the rapid human-to-human trans mission but 
also because of its consequences on social life, economics, 
and infrastructures.2 SARS-CoV-2 has spread rapidly, 
resulting in more than 7·27 million infections and 
413 000 deaths worldwide as of June 11, 2020.3 There have 
been more than 600 000 reported cases in the Asia-Pacific 
region (including the South-East Asia and Western Pacific 
regions defined by WHO) as of May 5, 2020. 
Abnormal liver function, or liver derangement, either in 
the form of hepatitis, cholestasis, or both, can be observed 
in patients with COVID-19. In an early report from China, 
raised serum alanine aminotransferase (ALT) was 
reported in 28 (28%) of 99 patients with COVID-19 and 
increased total bilirubin was reported in 18 (18%).4 The 
frequency and severity of liver dysfunction increases with 
the severity of COVID-19. In early SARS-CoV-2 infection, 
liver function tests are normal or minimally elevated. 
Liver histology shows microvascular steatosis, syncytial 
multinuclear hepatocytes, and mild lobular and portal 
activity.5 Electron microscopy shows mitochondrial 
swelling, endoplasmic reticulum dilatation, glycogen 
depletion, and impaired cell membranes. These micro-
scopic and ultrastructural features are all co-incident with 
the direct cytopathic effect of SARS-CoV-2 on the 
hepatocyte. In the severe acute respiratory syndrome 
(SARS) epidemic, severe acute respiratory syndrome 
coronavirus (SARS-CoV) viral particles and positive strand 
RNA with replicative intermediates were detected within 
hepatocytes, consistent with hepatocyte infection.6 
Evidence suggests that SARS-CoV-2 also replicates within 
hepatocytes.7 Hepatocytes and cholangiocytes express 
the ACE2 receptor necessary for cell entry.8 The minimal 
increase in aminotransferases and absence of marked 
lobular necroinflammation suggests that liver injury 
induced by SARS-CoV-2 is mild.
Although severe liver dysfunction has been described 
in patients with severe COVID-19, it is likely to be caused 
by other factors such as sepsis-associated cholestasis, 
ischaemic hepatitis from hypoxaemia and hypotension, 
and drug-induced liver injury. Many of the drugs being 
used in severe cases of liver dysfunction are associated 
with hepatotoxicity, including those used to treat 
SARS-CoV-2 infection such as remdesivir, lopinavir, and 
ritonavir. Additionally, exacerbation or reactivation of 
underlying chronic liver disease must be considered in 
any patient with chronic viral hepatitis or non-alcoholic 
fatty liver disease (NAFLD). There is evidence that 
SARS-CoV-2 might aggravate liver injury in patients with 
chronic viral hepatitis.9 Importantly, drug-induced liver 
injury during the treatment of SARS-CoV-2 infection 
should not be ignored.
Almost 10% of the estimated 5 billion people living in 
the Asia-Pacific region have chronic viral hepatitis.10 The 
increasing prevalence of NAFLD in the region further 
increases the probability of coexistence of COVID-19 and 
liver diseases.11 Furthermore, inadequate infra structure 
and insufficient health-care personnel trained in liver 
diseases are important issues that also need to be 
addressed in the Asia-Pacific region. Therefore, chronic 
liver diseases are prevalent in Asia-Pacific region and it is 
important to consider the potential impact of COVID-19 
on patients with underlying liver disease.12
This Rapid Review presents the recommendations of 
the Asia-Pacific Working Group for Liver Derangement 
during the COVID-19 Pandemic. This position statement 
focuses on the clinical management of patients who have 
been or who are at risk of developing liver derangement 
during the COVID-19 pandemic and does not cover 
specific management of patients with COVID-19. Regional 
hepatology associations have developed position papers to 
inform physicians on the care of patients with liver disease 
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during the COVID-19 pandemic.13–15 These position papers 
provide general high-level recom mendations on instit-
utional arrange ment and care principles for patients 
attending clinic and hospitals. Some recommendations, 
including telemedicine and decentralisation of care, might 
not apply in some parts of the Asia-Pacific region. In this 
position statement, developers from the Working Group 
formulated a list of questions of discrete clinical scenarios 
that physicians are facing in their daily practice. The 
recommendations in this position statement are based on 
specific clinical scenarios and will supplement other 
regional position papers on COVID-19.
Methods
This position statement was developed in compliance 
with the Institute of Medicine, Hong Kong, standards 
for trustworthy position statement, and uses the Grading 
of Recommendation Assessment, Development, and 
Evaluation approach (appendix p 1). In this approach, 
the quality of evidence (ie, certainty in evidence) is rated 
as A (high), B (moderate), or C (low) on the basis of the 
domains of precision, directness, consistency, and risk 
of bias and publication bias. The Working Group based 
its recommendations on the quality of evidence, balance 
of benefits and harms, patients’ values and preferences, 
and clinical context. Recommendations are graded as 
1 (strong), which apply to most patients with minimal 
variation, or as 2 (weak), which apply to most patients 
whose values and preferences are consistent with the 
course of action (appendix p 1).
The specific questions and scenarios specified for 
evaluation by the Working Group, as well as the grading 
before and after voting, are shown in the appendix 
(pp 2–5). A methodologist moderated and facilitated the 
process of question development. Multiple systematic 
reviews of the literature were searched to support the 
recommendations in this position statement. Members of 
the Working Group did a systematic review of the 
literature on specified domains of interest, thereby 
allowing them to provide recom mendations on different 
aspects of the clinical assessment and management of 
patients with COVID-19 and liver diseases. By multiple 
electronic communications, the Working Group finalised 
evidence summaries, and the final grading of evidence 
and recom mendations were determined by majority vote. 
The basis of recommendations are purely on consensus 
and some of them with low quality or certainty of evidence 
rated as C are not based on evidence, but are instead based 
on consensus as the evidence is currently insufficient.
Management of liver derangement in patients 
with COVID-19
Scenario 1: should off-label pharmacological treatment 
for COVID-19 be continued in the case of liver 
derangement? 
In patients with abnormal liver function, differential 
diagnoses include COVID-19 itself, ischaemic hepatitis, 
sepsis, drug-induced liver injury, and underlying causes of 
liver disease. In the Asia-Pacific region, where the 
prevalence of viral hepatitis is high, investigation of 
abnormal liver function should be tailored to the clinical 
presentation but should include serological tests for viral 
hepatitis (statement 1A; table 1). In regions with a low 
prevalence of viral hepatitis, it is reasonable to monitor 
liver function panel and to investigate underlying causes 
of liver disease if liver function tests fail to normalise 
within a reasonable time frame, arbitrarily from 8 weeks to 
12 weeks of diagnosis.
At present, there is no registered drug for the treatment 
of COVID-19.16 However, the US Food and Drug 
Administration issued an emergency use authorisation 
for the investigational antiviral drug remdesivir for the 
treatment of suspected or confirmed COVID-19 in 
hospitalised patients with severe disease on May 1, 2020.17 
Interferons, lopinavir–ritonavir, ribavirin, and chloro-
quine or hydroxy chloroquine are available in most places 
in the Asia-Pacific region but are registered for other 
indications; whereas, nucleoside analogues (remdesivir 
and galidesivir), monoclonal antibodies and interleukin 
(IL)-6 receptor blockers (eg, tocilizumab), convalescent 
plasma, hyperimmune γ globulin, or vaccines are not yet 
approved at the time of writing. Even after approval, the 
availability of drugs in countries in the Asia-Pacific 
region is likely to be variable. Although some drugs 
might appear promising in preclinical studies or early 
clinical experience, efficacy has not yet been supported in 
phase 2 and 3 clinical trials. For example, lopinavir–
ritonavir have been widely used for the treatment of 
COVID-19 because of preliminary evidence suggesting 
therapeutic benefits in patients with SARS.18 However, 
the drug did not improve clinical outcomes or increase 
viral clearance in a randomised controlled trial of 
199 patients with SARS-CoV-2 infection and hypoxia.19 
Although COVID-19 treatment is often used in the short 
term, because COVID-19 is a potentially life-threatening 
acute illness, the risk–benefit ratio should be considered 
in the decision-making process. Off-label COVID-19 
therapies might be used with caution and close 
monitoring in patients with abnormal liver function 
(statement 1B; table 1).
Table 2 lists the drugs that have been used for the 
treatment of COVID-19 and their associated liver safety. It 
is important to note that liver derangement might be due 
to drug-induced liver injury, underlying medical disease, 
or concomitant medications. In patients who do not have 
COVID-19, elevation in concentrations of serum ALT or 
aspartate amino transferase (AST) has been described 
in individuals receiving interferon, lopinavir–ritonavir, 
tocilizumab, or remdesivir.20–22 Isolated cases of severe 
liver injury in patients with COVID-19 have also been 
reported rarely.23 The drugs, particularly corticosteroids, 
might also cause indirect liver injury through reactivation 
of underlying liver diseases such as chronic hepatitis B 
virus (HBV) infection.24
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1A Patients with COVID-19 and persistent liver derangement should have standard investigations for liver diseases; the choice of investigations 
would depend on the clinical presentation and pattern of liver injury but should involve at least serological tests for viral hepatitis
C 1
1B Patients with abnormal liver function should be closely monitored when using off-label lopinavir–ritonavir, chloroquine, hydroxychloroquine, 
and tocilizumab, preferably monitored in the setting of clinical trials
C 1
1C Off-label treatment for COVID-19 should be withheld in the case of moderate-to-severe (ie, category 2–3) liver injury C 1
2A Clinicians should test liver function in hospitalised patients with COVID-19 C 1
2B The optimal interval for liver tests is uncertain; however, it would be reasonable to monitor liver tests twice weekly in patients on potentially 
hepatotoxic medication, patients with pre-existing liver disease, and more frequently in any patients with abnormal liver function
C 2
3A Patients with COVID-19 and liver derangement should have investigations for the underlying cause, including screening for common liver 
diseases (eg, viral hepatitis); there is no evidence to support routine screening for chronic liver diseases in patients with normal liver tests
B 1
3B Screening for other causes of liver disease might wait until abnormal liver function persists beyond recovery of COVID-19 C 2
4A If systemic corticosteroids or other potent immunosuppressants (eg, tocilizumab) are used as COVID-19 therapy for 7 days or longer, screening 
for HBsAg is recommended; antiviral therapy for HBV should be initiated to avoid HBV reactivation and hepatitis flare in patients with known 
HBV infection
B 1
4B Antiviral therapy for HBV newly diagnosed at the time of presentation with COVID-19 should be started according to the existing international 
guidelines
A 1
4C Concomitant use of tenofovir disoproxil fumarate or tenofovir alafenamide with lopinavir–ritonavir is relatively contraindicated as drug 
concentration of tenofovir might be increased; tenofovir might be temporarily switched to entecavir during the use of lopinavir–ritonavir in the 
absence of entecavir resistance
B 1
4D Do not stop oral nucleoside antiviral therapy for HBV at the time of COVID-19 to avoid the risk of HBV reactivation and clinical flare B 1
5A Concomitant use of protease inhibitor-containing DAA regimens for hepatitis C virus with lopinavir–ritonavir is contraindicated A 1
5B DAAs should be continued if being taken at the time of COVID-19 diagnosis, unless drug–drug interactions would be problematic or patients are 
in critical condition
B 1
5C If clinically significant drug–drug interactions with COVID-19 therapies are present, DAAs should be deferred until after COVID-19 A 1
5D Drug–drug interactions between some new COVID-19 therapies and DAAs should be closely monitored as data are scarce C 1
6A Have heightened awareness of adverse clinical outcomes in patients with NAFLD who have COVID-19, especially if they have diabetes C 1
6B Blood pressure and glycaemic control should be monitored and managed in patients with NAFLD who have COVID-19 C 2
7A Prioritise resources to continue usual surveillance imaging (with or without tumour markers) in patients who need hepatocellular carcinoma 
surveillance the most (eg, patients with cirrhosis or high hepatocellular carcinoma risk scores)
B 1
7B An arbitrary delay of 3 months in patients with relatively low risk of hepatocellular carcinoma is reasonable and might be necessary if COVID-19 
outbreaks are ongoing in the region
C 2
8A Patients with hepatocellular carcinoma who have COVID-19 should have their hepatocellular carcinoma treatment deferred until after recovery 
from COVID-19
C 2
8B Bridging transarterial chemoembolisation, radiofrequency ablation, or systemic chemotherapy might be considered in selected patients with 
hepatocellular carcinoma who have COVID-19 when surgical resection is deferred
C 2
9A Postponement of elective upper gastrointestinal endoscopic examination for variceal screening in patients with no history of gastrointestinal 
bleeding until a COVID-19 outbreak is under control is reasonable, and might be necessary if COVID-19 outbreaks are ongoing in the region
C 1
9B Non-invasive tools (eg, Baveno VI criteria, platelet-to-liver stiffness measurement ratio, liver and spleen stiffness measurement) might be used to 
identify patients who are at high risk of having clinically significant varices
B 1
9C Endoscopic eradication of oesophageal varices should be done following a variceal bleed A 1
9D In the case that emergency or urgent upper endoscopy is warranted in suspected or confirmed cases of COVID-19, it should be done under a 
negative-pressure room when available with strict isolation precautions, and all endoscopy personnel should wear appropriate personal 
protective equipment, including N95 respirator and waterproof protective gown
B 1
10A Reduce the number of patients coming to transplantation clinic per session for assessment; only assess patients with hepatocellular carcinoma or 
patients with high MELD scores who are likely to benefit from immediate liver transplantation listing
C 1
10B Telehealth should be available to most transplantation centres C 2
10C Clear instruction to patients awaiting liver transplantation to maintain physical distancing and to not travel during the COVID-19 pandemic B 1
10D All potential donors (cadaveric and live donors) and recipients should be tested for SARS-CoV-2 RNA and transplantation will only proceed with 
negative donors to negative recipients
B 1
11A Check for any drug–drug interactions if COVID-19 therapies are needed in patients after transplantation A 1
11B It is not necessary to reduce immunosuppression or stop mycophenolate mofetil for asymptomatic patients after transplantation B 1
11C Patients or their caregivers with COVID-19 symptoms should not visit the liver transplantation clinic B 1
11D All patients after transplantation should avoid an unnecessary outpatient visit; an arbitrary delay of 3 months is reasonable and might be 
necessary if COVID-19 outbreaks are ongoing in the region
B 1
(Table 1 continues on next page)
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Because liver derangement is common in COVID-19, 
the difficulty in establishing the diagnosis of drug-
induced liver injury poses a clinical dilemma. The 
Working Group suggest following established guide lines 
to manage suspected cases of drug-induced liver injury.25 
In the case of elevated ALT, AST, or both, standard 
investigations should be done to rule out other liver 
diseases such as acute or chronic viral hepatitis and 
autoimmune liver diseases. For the sake of infection 
control, clinicians should avoid sending patients with 
COVID-19 to another area or facility for liver imaging, 
unless there are clinical symptoms and signs of biliary 
pathology. Bedside ultrasonography can be done to look 
for cirrhosis, hepatocellular carcinoma, and biliary 
pathology. If bedside ultrasonography does not provide 
high-quality imaging, proper imaging at the radiology 
department with adequate infection control could be 
arranged in an emergency situation (eg, ruptured hepato-
cellular carcinoma, acute cholan gitis, or cholecys titis). 
Routine FibroScan examination should be deferred. The 
severity of liver injury might be classified according to 
the recommendations by the US Drug-Induced Liver 
Injury Network or International Drug-Induced Liver 
Injury Expert Working Group (appendix p 6).9,26 As the 
benefits of off-label treatments are uncertain, in the case 
of moderate-to-severe liver injury (ie, ALT >5 times upper 
limit of normal [ULN] or alkaline phosphatase [ALP] 
>2 times ULN, and total bilirubin >2 times ULN or 
presence of coagulopathy or clinical decompensation) it 
would be reasonable to stop the drug (statement 1C; 
table 1). If the treatment for COVID-19 is given in a 
clinical trial, the management of liver derangement 
should follow the study protocol.
Scenario 2: should all patients with COVID-19 have liver 
function checked routinely?
Liver derangement is common in patients with 
COVID-19. It is reported that 16–53% of patients had 
elevated ALT and AST during the course of illness 
(appendix p 7).4,27–32 In general, patients with liver 
derangement tend to have severe COVID-19. It is 
important to note that clinically significant abnormalities 
of liver function tests with hepatic decom pensation 
are rare.
There are different reasons for liver derangement in 
COVID-19. Although SARS-CoV-2 binds ACE2 with high 
affinity and ACE2 is present in the biliary system,33 the 
normal concentrations of serum alkaline phosphatase in 
most patients with COVID-19 suggests that this is not an 
important mechanism underlying the association with 
liver derangement.
By contrast, most cases of liver derangement will 
reflect either underlying chronic liver disease, sepsis-
related chol estasis and inflammatory changes, or 
hepatotoxicity from concomitant medications. Because 
liver derangement might contraindicate particular 
medications, it is necessary to monitor liver tests in 
hospitalised patients with COVID-19, although the 
optimal interval for liver tests is unknown (statements 2A 
and 2B; table 1). It is important to note that the current 
data on liver derangement in patients with COVID-19 
were derived from cohorts of hospitalised patients. The 
freq uency and severity of liver injury in asymptomatic 
patients or in individuals with mild symptoms is 
unknown.
Scenario 3: should all patients with COVID-19 be 
routinely screened for common chronic liver diseases on 
the basis of local prevalence?
Asia has a high prevalence of chronic hepatitis B, chronic 
hepatitis C, alcohol-related liver disease, and NAFLD.10,34,35 
In the case of abnormal liver function, investigations for 
acute and chronic liver diseases according to the clinical 
presentation and local epidemiology would clarify the 
clinical picture and facilitate management. In some 
cases, notably chronic viral hepatitis, specific treatment 
of underlying liver disease might also improve liver 
tests. Routine testing for HBV was recommended in all 
individuals born in the Asia-Pacific region before the 
introduction of universal neonatal vaccination. Routine 
testing for HCV was recommended in individuals with a 
history of injecting drug use, blood transfusion, or organ 
transplantation before the introduction of donor 
screening. Otherwise, there is no evidence to support 




(Continued from previous page)
11E Emphasise well known prevention measures to patient after transplantation: frequent hand washing, cleaning frequently touched surfaces, 
staying away from large crowds, staying away from individuals who are ill, etc.
B 1
12A In patients with known decompensated cirrhosis, decisions about intensive care unit support should be made on a case-by-case basis, taking into 
account baseline liver function, previous episodes of liver decompensation, and transplantation eligibility
C 2
12B Spontaneous bacterial peritonitis in patients with COVID-19 and decompensated cirrhosis should be treated with broad-spectrum antibiotics 
with no drug–drug interactions with the COVID-19 therapies
C 2
Quality of evidence (ie, certainty in evidence) is rated as high (A), moderate (B), or low (C) on the basis of the domains of precision, directness, consistency, and risk of bias and publication bias. Strength of 
recommendations are graded as strong (1), which apply to most patients with minimal variation, or as weak (2), which apply to most patients whose values and preferences are consistent with the course of 
action. HBV=hepatitis B virus. DAA=direct-acting antiviral. NAFLD=non-alcoholic fatty liver disease.  
Table 1: Recommendation statements on the management of patients with liver derangement during COVID-19 pandemic
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routine screening for chronic liver diseases in patients 
with persistently normal liver tests (statement 3A; 
table 1).
Causes of liver disease other than chronic viral hepatitis 
and NAFLD might only account for less than 10% of 
chronic liver diseases in the region.11 Therefore, screening 
for uncommon causes not previously diagnosed 
(eg, autoimmune hepatitis, haemochromatosis, Wilson’s 
disease, etc) might be done only if the abnormal liver 
function persists beyond recovery of COVID-19 
(statement 3B; table 1).
Management of patients with underlying liver 
disease
Scenario 4: should patients with COVID-19 and chronic 
HBV infection have antiviral therapy for HBV that 
started when liver derangement developed? What are 
the risks of drug–drug interactions of medications for 
chronic liver diseases and the pharmacological 
treatment for COVID-19?
Patients with chronic liver disease might be susceptible to 
liver damage from some coronavirus infections, including 
Middle East respiratory syndrome (MERS) and SARS.36 It 
is not clear whether such patients are also susceptible to 
liver damage from SARS-CoV-2 infection. Some studies 
from China report a lower prevalence of HBV infection in 
patients hospitalised with COVID-19 than in the general 
population.28 In patients with chronic HBV infection who 
develop SARS-CoV-2 superinfection, elevation of serum 
aminotransferase concentrations might be secondary to 
chronic hepatitis B.4 Systemic high-dose corticosteroid 
and tocilizumab have been advocated for treatment of 
patients with COVID-19 who are critically ill.29,37 This 
regimen might cause HBV reactivation, hepatitis flare, 
and acute liver failure in patients with chronic HBV 
infection. Therefore, screening for HBsAg is recom-
mended, and antiviral prophylaxis with nucleoside 
analogues is recommended in all patients with severe 
COVID-19 who test positive for HBsAg during corti-
costeroid therapy (statement 4A; table 1).38
It would be reasonable to initiate antiviral therapy for 
HBV newly diagnosed at the time of presentation with 
COVID-19 when patients fulfil the treatment criteria 
recommended by international guidelines—namely, HBV 
DNA above 2000 IU/mL, ALT more than ULN (European 
Association for the Study of the Liver recommendations)39 
or 2 times ULN (Asian Pacific Association for the Study 
of Liver and American Association for the Study of 
Liver Diseases recommendations),40,41 or compensated or 
decompensated cirrhosis with detectable HBV DNA 
(statement 4B; table 1).
Current first-line nucleoside analogues have excellent 
long-term safety.42 Hence, if patients do not exactly fulfil 
the treatment criteria or are in the grey zone (eg, ALT 
mildly elevated to 1–2 times ULN), it is reasonable to 
start antiviral therapy as long as the patients accept 
Risk of liver injury Safety in hepatic impairment
Immunomodulators
Interferon alfa ALT might increase to >2 times ULN in >25% of patients with 
chronic viral hepatitis; jaundice and decompensation rare but 
reported
Contraindicated in decompensated liver disease
Interferon beta ALT might increase to >3 times ULN in 10% of patients; 
jaundice and decompensation rare but reported
Not specified
Corticosteroids Risk of HBV reactivation; could trigger or worsen non-alcoholic 
steatohepatitis
No evidence of increased toxicity in hepatic impairment
Antivirals
Favipiravir <10% of patients might have self-limiting ALT elevation Not specified
Lopinavir–ritonavir ALT might increase to >5 times ULN in 5% of patients; jaundice 
and decompensation rare but reported
Increased risk of hepatotoxicity in patients with chronic liver diseases, 
ALT elevation, or hepatic decompensation
Remdesivir Mild ALT elevation to >2 times ULN; mild-to-moderate AST 
elevation to >3–4 times ULN
Not specified
Ribavirin ALT elevation uncommon when used in isolation No evidence of increased toxicity in hepatic impairment
Nitazoxanide Uncommon Safety in hepatic impairment not studied
Antimalarials
Chloroquine ALT elevation in <5% of patients Not specified but chloroquine is known to concentrate in the liver; 
should be used with caution in patients with hepatic disease or alcohol 
misuse, or in conjunction with known hepatotoxic drugs
Hydroxychloroquine ALT elevation in <5% of patients Should be used with caution in patients with hepatic disease or alcohol 
misuse, or in conjunction with known hepatotoxic drugs
Monoclonal antibody
Tocilizumab ALT elevation in >20% of patients; ALT increase to >5  times 
ULN in <1% of patients
Safety in patients with hepatic impairment and cytokine release 
syndrome has not been formally studied
ALT=alanine aminotransferase. ULN=upper limit of normal. HBV=hepatitis B virus. AST=aspartate aminotransferase.
Table 2: Drugs used for the treatment of COVID-19 and their liver safety
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long-term treatment. Drug–drug interactions might 
occur between agents used to treat COVID-19 and 
treatments for HBV. It would be advisable to check the 
potential drug–drug interactions with reliable online 
platforms (eg, the Liverpool Drug Interaction Group).
In general, there are no major drug–drug interactions 
between the therapeutic options for COVID-19 and 
nucleoside analogues for HBV that lead to absolute 
contraindication. Coadministration of lopinavir–ritonavir 
and tenofovir disoproxil fumarate might increase the 
concentration of tenofovir by 32–51%, whereas 
coadministration of lopinavir–ritonavir and tenofovir 
alafenamide might increase the concentration of tenofovir 
by 275–316%.43 Therefore, there might be increased risk of 
renal impairment. No dose adjustment of tenofovir 
disoproxil fumarate or tenofovir alafenamide fumarate is 
recom mended, but close monitoring of renal function and 
for adverse reactions associated with tenofovir is required. 
Alternately, tenofovir disoproxil fumarate or tenofovir 
alafenamide fumarate might be switched to entecavir 
during use of lopinavir–ritonavir (statement 4C; table 1).
Virological or biochemical relapse occur in a substantial 
proportion of patients with chronic hepatitis B after 
stopping oral antiviral drugs.44,45 Given that stopping 
nucleoside analogues might lead to HBV reactivation and 
clinical flare,46 it is not advisable to halt such treatment in 
patients with COVID-19 (statement 4D; table 1).
Scenario 5: what are the potential drug–drug 
interactions between direct-acting antiviral (DAA) 
therapy for chronic HCV infection and pharmacological 
treatment for COVID-19? 
Table 3 summarises the drug–drug interactions between 
COVID-19 therapies and DAAs. Concomitant use of 
protease inhibitor-containing DAA regimens (elbasvir–
grazoprevir, glecaprevir–pibrentasvir, and sofosbuvir–
velpatasvir–voxilaprevir) with lopinavir–ritonavir might 
increase the drug concentrations of protease inhibitor and, 
hence, risk of ALT elevations because lopinavir is a potent 
OATP1B (SLCO1B1) inhibitor. Therefore, concomitant use 
of these three DAA regimens with lopinavir–ritonavir is 
contraindicated (statement 5A; table 1). Use of chloroquine, 
hydroxychloroquine, and ribavirin is generally safe as no 
obvious drug–drug interactions have been reported.
As most COVID-19 therapies do not have considerable 
drug–drug interactions with DAAs, DAAs should be 
continued to maximise the sustained virological 
response rate (statement 5B; table 1). Premature 
cessation of DAA therapy might reduce this rate from 
nearly 100% to 74%.47
For more on the Liverpool Drug 
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Toclizumab NA NA NA NA NA NA NA NA
NA=not available.
Table 3: Potential drug–drug interactions between COVID-19 therapies and direct-acting antiviral therapy for the treatment of chronic hepatitis C or oral nucleoside analogues for the 
treatment of chronic hepatitis B
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Any use of COVID-19 therapies in patients who are 
receiving DAAs should be closely monitored for potential 
adverse events. Because hepatitis flare related to HCV 
following DAA termination is very rare,48 DAA might 
be withheld or terminated prematurely if there are 
problematic drug–drug interactions, or if patients are in 
critical condition (eg, under positive pressure ventilation 
or intubated) (statement 5C; table 1).
Data for some new COVID-19 therapies are insufficient, 
either because the therapies are relatively new 
(eg, remdesivir or tocilizumab), or because there are no 
studies of concomitant use of DAAs in combination with 
existing therapies (eg, interferon). As such, their use in 
patients also receiving DAAs should be closely monitored 
(statement 5D; table 1).
Scenario 6: what are the precautions and treatments 
recommended for patients with NAFLD? 
Patients with NAFLD might have metabolic comor bidities 
such as type 2 diabetes, hypertension, and obesity, putting 
them at increased risk of a severe course of COVID-19 
(statement 6A; table 1). Although studies specifically 
looking into the clinical course of COVID-19 in patients 
with NAFLD are pending, diabetes has been repeatedly 
found to be associated with admission to the intensive 
care unit, mechanical ventilation, or death.28 A study from 
China reporting use of CT scan showed that fatty liver was 
associated with increased risk of severe and critical illness 
among patients with COVID-19 aged younger than 
60 years.49 Furthermore, patients with NAFLD might be 
more susceptible to drug-induced liver injury.26
Both hyperglycaemia and hypoglycaemia have been 
reported in patients with diabetes diagnosed with 
COVID-19.50 Although the optimal amount of glycaemic 
control in patients with critical COVID-19 is a matter of 
debate, it would be prudent to avoid hypoglycaemia and 
severe hyperglycaemia as they have been associated with 
inhospital mortality. On the basis of existing data, it is 
reasonable to aim for a blood glucose target of 10 mmol/L 
(180 mg/dL).51 Additionally, although patients with NAFLD 
commonly have hypertension, shock can occur in patients 
with severe COVID-19. Monitoring and timely adjustment 
of medications for these metabolic disorders are likely to 
reduce the risk of adverse outcomes (statement 6B; table 1).
Scenario 7: how should hepatocellular carcinoma 
surveillance be done during the COVID-19 pandemic? 
Hepatocellular carcinoma is the fifth most common 
cancer in men and the ninth most common in women 
worldwide.52 This type of cancer has a high mortality rate 
and represents the third most frequent cause of death 
from cancer globally (782 000 deaths in 2018).52 Regular 
surveillance can facilitate early detection of hepatocellular 
carcinoma that is still manageable by curative treatment, 
leading to improved survival.53 As resources are scarce 
in the COVID-19 pandemic, in terms of staffing and 
scanning sessions, resources should be prioritised to 
continue usual surveillance imaging in patients who are 
most in need of hepatocellular carcinoma surveillance 
(statement 7A; table 1).
However, there should be a balance between the risk of 
being infected with SARS-CoV-2 and the risk of 
hepatocellular carcinoma while attending facilities for 
hepatocellular carcinoma surveillance. Efforts should be 
made to minimise risk of COVID-19 exposure; for 
example, community-based radiology is recommended 
where available to reduce the risk of iatrogenic exposure. 
In hospitals or regions with high prevalence of COVID-19, 
it is reasonable to delay planned hepatocellular carcinoma 
screening by 3 months because, although hepatocellular 
carcinoma surveillance every 6 months is recommended, 
hepato cellular carcinoma surveillance every year also 
provides benefits with no difference in overall survival.54 
Furthermore, because of the shortage of health-care 
resources and staffing, some non-urgent health-care 
services might be cancelled or delayed to facilitate 
reallocation to urgent services during the COVID-19 
pandemic.55 Therefore, it would be reasonable and 
necessary to have an arbitrary delay, probably around 
3–6 months, if there is substantial community 
transmission of SARS-CoV-2 in the region (statement 7B; 
table 1).
Scenario 8: how should patients with hepatocellular 
carcinoma be managed during the COVID-19 pandemic? 
Detailed discussions about hepatocellular carcinoma 
management during the COVID-19 pandemic have been 
discussed by various oncology societies.56,57 Because most 
patients with COVID-19 recover within 3–4 weeks,28 it 
would be reasonable to defer treatment of hepatocellular 
carcinoma for a few weeks after the recovery of COVID-19 
(statement 8A; table 1).
Among the various treatment methods for hepato-
cellular carcinoma, surgical resection would be affected 
the most during the COVID-19 pandemic. On one hand, 
the demand to expand ventilation capacity for patients with 
COVID-19 has resulted in a shortage of anaesthetists to 
support surgery and other procedures such as ablation, 
which require a general anaesthetic. On the other hand, 
spreading SARS-CoV-2 aerosol by general anaesthesia 
in patients with confirmed or undiagnosed COVID-19 
might pose a risk to health-care personnel in the operating 
theatre. Bridging therapy with transarterial chemo embo-
lisation, radiofrequency ablation, or systemic chemo-
therapy might be offered in place of potentially curative 
interventions (statement 8B; table 1). Coupling this therapy 
with close monitoring, such as imaging and  α-fetoprotein, 
should be used to reduce the risk of patients progressing 
beyond criteria for transplantation, resection, or ablation.
Scenario 9: how should variceal screening be done 
during the COVID-19 pandemic? 
During the COVID-19 pandemic, various groups have 
advocated to defer non-urgent, elective endoscopic 
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examinations.58,59 Upper gastrointestinal endoscopy is 
likely to be a high-risk procedure because respiratory and 
gastric secretions might contain high viral loads of 
SARS-CoV-2. Upper gastrointestinal endoscopy can induce 
aerosol spreading of COVID-19 due to blowing air and 
suction through the nose and throat. However, variceal 
bleeding is a potentially life-threatening com pli cation in 
patients with liver cirrhosis.60 Patient outcome would be 
much poorer if patients developed variceal bleeding and 
presented as an endoscopic emergency, compared with 
elective prophy lactic band ligation of varices.61 Similar to 
hepatocellular carcinoma surveillance, there should be a 
balance between the risk of variceal bleeding and the risk 
of getting COVID-19 during the process of variceal 
surveillance. Furthermore, the risk of infecting health-care 
personnel in the endoscopy suite, nosocomial outbreaks, 
and short supply of personal protective equipment should 
all be considered. Hence, it would be reasonable and 
necessary to have an arbitrary delay, probably up to 
3 months, if COVID-19 outbreaks are ongoing in the 
region. We recommend that elective upper gastrointestinal 
endoscopic examination for variceal screening is 
postponed in patients with no history of gastrointestinal 
bleeding until the COVID-19 outbreak is under control, 
and postponement might be necessary if COVID-19 
outbreaks are ongoing in the region (statement 9A; table 1).
To reduce the risk of nosocomial outbreaks and usage of 
personal protective equipment, non-invasive assessments 
such as Baveno VI criteria,62 platelet-to-liver stiffness 
measurement ratio,63 liver stiffness measurement, and 
spleen stiffness measurement with transient elastography 
have been widely studied and found to have good predictive 
value to identify patients who have clinically significant 
varices64 and who are at risk of future variceal bleeding 
(statement 9B; table 1).65 Patients with cirrhosis might first 
undergo transient elastography examination. Such a 
strategy might be able to reduce the need for at least 50% 
of endoscopic examinations,38,62 thus saving many sets of 
personal protective equipment and reducing the risk of 
infecting endoscopy personnel. 
Endoscopic eradication of oesophageal varices should 
be done following a variceal bleed (statement 9C; table 1). 
Although variceal eradication would usually last for 
6–12 months after repeated band ligation, oesophageal 
variceal recurrence after variceal eradication might occur 
at a median time of 13·4 months.66 Prophylactic coverage 
of non-selective β blockers for patients at high risk might 
be an alternative if screening cannot be arranged.67
For patients with suspected, probable, or confirmed 
COVID-19, endoscopy should only be done for emergency 
or urgent indications, with strict isolation precautions 
and ideally in a negative-pressure room (statement 9D; 
table 1). As some endoscopy units might not have a 
negative-pressure room, the procedure can be done in a 
venue outside of the endoscopy centre (eg, with negative 
pressure in the operation theatre or in a room with 
improved ventilation).58
Scenario 10: what are the special arrangements and 
precautions in patients needing liver transplantation 
during the COVID-19 pandemic?
The well established risk factors of severe illness among 
patients with COVID-19 include individuals aged older 
than 60 years with advanced frailty.68 Other comorbidities 
associated with worse outcome include congestive heart 
failure, chronic lung disease, diabetes, hypertension, 
renal failure, and liver failure. Patients with either acute 
liver failure or decompensated cirrhosis have a poor 
outcome following SARS-CoV-2 infection.9 However, it is 
not yet known whether recipients of liver transplant 
without comorbidities are at greater risk of developing 
severe COVID-19 than are non-transplant patients. Early 
reports have highlighted the importance of paying 
attention to long-term liver transplant patients with 
metabolic comorbidities.69,70 Immunosuppression per se 
does not appear to affect the natural history of SARS-CoV-2 
infection. Theoretically, immuno sup pression could 
prevent progression to COVID-19 through cytokine 
down regulation. Steroids and hydroxy chloro quine have 
been used in the most critically ill patients with COVID-19 
in intensive care, albeit with minimal success because 
these patients often have irreversible sepsis or multiorgan 
failure. To reduce the risk of COVID-19 in patients with 
advanced liver disease, priority should be given to 
individuals who need liver transplant urgently—namely, 
patients with hepatocellular carcinoma or high MELD 
scores (statement 10A; table 1).71
Telehealth home monitoring has been found to be 
feasible and useful in recipients of liver transplant;72 
therefore, it should be available to most transplantation 
centres and expanded to patients before transplantation 
if telehealth facilities are available in some parts of the 
Asia-Pacific region (statement 10B; table 1).73
Considering that SARS-CoV-2 can be transmitted from 
asymptomatic individuals, including children, patients 
awaiting liver transplantation should strictly adopt 
physical distancing or not travel during the COVID-19 
outbreak (statement 10C; table 1).74
Both organ donors and recipients might be at risk of 
incubating asymptomatic or active COVID-19 through 
contact with a patient who has had the infection or by 
community and hospital exposure during the outbreak.75 
Unrecognised COVID-19 in recipients of organ donation 
considerably increases the risk of severe immune 
suppression and infection after transplantation, which 
might lead to multisystem organ damage or death.76 The 
donor with unidentified SARS-CoV-2 infection might 
also spread the virus to multiple recipients. Patients who 
develop COVID-19 after transplantation might have 
prolonged fever, lymphopenia, poor recovery of liver 
function, and prolonged detectability of SARS-CoV-2.77 
Thus, strict screening guidance for recipients and 
donors of organ transplants needs to be developed to 
help to reduce further transmission (statement 10D; 
table 1).
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Scenario 11: what are the special arrangements and 
precautions in managing patients after transplantation 
during the COVID-19 pandemic?
Table 4 summarises the drug–drug interactions between 
COVID-19 therapies and immunosuppressive agents 
commonly used in liver transplantation. Drug–drug 
inter actions might occur between agents that are 
metabolised via cytochrome P450 enzymes (eg, 
ciclo sporin, sirolimus, and tacrolimus; statement 11A; 
table 1). Lopinavir–ritonavir are potent inhibitors of 
CYP3A4, which is involved in the metabolism of 
calcineurin inhibitors, sirolimus, and tacrolimus. If 
lopinavir–ritonavir are used, we recommend that tacro-
limus dosage is reduced to 2–5% of baseline because of 
drug–drug interactions.
Azathioprine, ciclosporin, and mycophenolate mofetil 
are commonly used immuno suppressive agents in 
patients after transplantation with no or minimal drug–
drug interactions with COVID-19 therapies (statement 11B; 
table 1).78
Transplant recipients aged older than 60 years and 
immunosuppressed patients are more likely to acquire 
SARS-CoV-2 infection.70 Innate immune response might 
be the main driver for lung injury due to COVID-19; 
therefore, immunosuppression might possibly protect 
patients with COVID-19 from severe illness.78 To date, data 
do not suggest that immunosuppression after trans-
plantation is a risk factor for mortality associated with 
SARS (2003–04) or MERS (2012–present).78 Nonethe less, 
immunosuppression might prolong viral shedding in 
patients with COVID-19 after transplantation.76 Patients 
with COVID-19 symptoms should not be evaluated in the 
liver transplantation clinic. The clinic visit should be 
deferred for at least 14 days, and medication refill should 
be offered to avoid acute withdrawal of immunosuppressive 
therapy (statement 11C; table 1).
If clinical evaluation of a patient with suspected or even 
confirmed COVID-19 after transplantation is deemed 
necessary, use of an outpatient clinic or a site dedicated 
for this purpose with adequate personal protective 
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Table 4: Potential drug–drug interactions between COVID-19 therapies and immunosuppressive agents
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equipment provided to the health-care personnel might 
be considered. There is evidence showing the spread of 
COVID-19 from asymptomatic patients;79 therefore, if 
community COVID-19 outbreaks are ongoing in the 
region, after transplantation all patients should avoid 
unnecessary outpatient visit and arbitrarily delay their 
visit to a time when community outbreak is mostly under 
control (statement 11D; table 1).
Appropriate preventive measures remain the corner-
stone of avoiding infection with COVID-19 (statement 11E; 
table 1).80
Scenario 12: should patients with decompensated 
cirrhosis be sent to the intensive care unit if they 
develop respiratory failure due to COVID-19? 
Presence of cirrhosis is an established risk factor of 
severe illness among patients with COVID-19.68 From the 
real-world combined data from SECURE Cirrhosis and 
COVID-Hep in April, 2020, which included 82 patients 
with cirrhosis (43 decompensated cirrhosis), a third of 
patients with cirrhosis died. Nearly two-thirds of the 
patients who died were not taken to the intensive care 
unit before their death.80 It is generally understandable 
and justifiable to give priority to maximising the number 
of patients who might survive treatment (statement 12A; 
table 1).55
To date, there is no study looking into the specific 
management approach for patients with COVID-19 who 
develop spontaneous bacterial peritonitis. Spontaneous 
bacterial peritonitis occurred in eight (3%) of 259 patients 
with cirrhosis who developed COVID-19, which is the 
largest cohort of patients with cirrhosis and COVID-19 
published to date.9 However, no specific management 
exists for patients with COVID-19 who develop 
spontaneous bacterial peritonitis (statement 12B; table 1).
Future perspectives
Because COVID-19 is a new disease, much more data 
are needed to improve our understanding of its impact 
on the liver and of the appropriate management of 
patients with liver diseases. As liver impairment is a 
common observation among patients with COVID-19, 
basic investigations on the causes of liver disease, 
including viral hepatitis serology tests, should be done 
in all future patients with COVID-19, particularly in the 
Asia-Pacific region where HBV is prevalent. With new 
antiviral drugs being developed for COVID-19, the 
potential drug–drug interactions and liver toxicity must 
be thoroughly evaluated. Recom mendations might need 
to be updated when a vaccine for COVID-19 becomes 
available, and safety and efficacy of such a vaccine has to 
be proven in patients with advanced liver disease and in 
recipients of liver transplant.
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